Deals add antibacterial programs to firm’s antiviral-focused pipeline. Australian anti-infectives company Biota reported separate agreements to purchase key assets and drug development programs from ...
A novel antibacterial medicine that kills the superbug MRSA is being developed under a new scheme launched by the Wellcome Trust. The Seeding Drug Discovery initiative is aimed at catalysing the ...
Galapagos NV and Prolysis Ltd have announced an extension of the research collaboration started earlier this year. BioFocus, the service division of Galapagos, is progressing a lead optimisation ...
Biota said yesterday it had obtained the key assets and programs of drug discovery company Prolysis based at Oxford in England for $10.8 million in Biota shares and a deferred consideration of up to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results